Jose Eduardo Lopez

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignee: Eli Lilly and Company. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jose Eduardo Lopez. Retrieved from https://idiyas.com/inventor/jose-eduardo-lopez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 31.3

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

16 out of 4,509

Eli Lilly and Company

patents

Years Active: 2002-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404298 - Glucocorticoid receptor agonists (2025-09-02),

2. 11787834 - Glucocorticoid receptor agonists (2023-10-17),

3. 10836773 - 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds (2020-11-17),

4. 10752632 - 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds (2020-08-25),

5. 9522923 - Selective BACE1 inhibitors (2016-12-20),

6. 8889856 - Tetrahydropyrrolothiazine compounds (2014-11-18),

7. 8772282 - Tetrahydropyrrolothiazine compounds (2014-07-08),

8. 8629270 - Tetrahydropyrrolothiazine compounds (2014-01-14),

9. 7943795 - Vitamin D receptor modulators (2011-05-17),

10. 7932284 - Indole sulfonamide modulators of progesterone receptors (2011-04-26),

11. 7595403 - Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors (2009-09-29),

12. 7414063 - Inhibitors of Akt (protein kinase B) (2008-08-19),

13. 7250430 - Thiophene-and thiazolesulfonamides as antineoplastic agents (2007-07-31),

14. 7217727 - Phospholipase inhibitors (2007-05-15),

15. 7084170 - Thiophene-amd thiazolesulfonamides as antineoplastic agents (2006-08-01),

Title: Jose Eduardo Lopez – Pioneering Innovator in Pharmaceutical Research

Introduction:

Jose Eduardo Lopez, a distinguished inventor based in Fishers, IN (US), has made significant contributions to the field of pharmaceutical research with his groundbreaking inventions. With a total of 15 patents to his name, Lopez's work has been instrumental in the development of novel treatments for autoimmune and inflammatory diseases.

Latest Patents:

Among his recent patents, Lopez has introduced Glucocorticoid receptor agonists, which are compounds aimed at treating autoimmune and inflammatory conditions such as atopic dermatitis and rheumatoid arthritis. Additionally, his invention of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds shows promise in the treatment of neurodegenerative diseases like Alzheimer's.

Career Highlights:

Lopez is a key figure at Eli Lilly and Company, a leading pharmaceutical organization known for its innovative research and development initiatives. His expertise in medicinal chemistry and drug discovery has propelled him to the forefront of the industry, earning him acclaim for his inventive spirit and commitment to advancing healthcare solutions.

Collaborations:

In his research endeavors, Lopez has collaborated closely with esteemed colleagues such as Ho-Shen Lin and Michael Enrico Richett. Together, they have synergized their talents and expertise to push the boundaries of scientific innovation, resulting in the development of cutting-edge therapies with the potential to transform patient care.

Conclusion:

Jose Eduardo Lopez's career exemplifies the essence of innovation and ingenuity in the realm of pharmaceutical research. Through his dedication to pioneering new treatments for complex medical conditions, Lopez continues to shape the landscape of healthcare with his inventive spirit and unwavering commitment to advancing scientific knowledge.

Profile summary based on public USPTO records.